The European Medicines Agency granted positive Scientific Advice to
Prima BioMed Ltd. (Nasdaq: PBMD) for the breast cancer treatment IMP321 sending the stock price soaring 39 cents to $1.59.
EMA grants positive Scientific Advice to Prima BioMed
July 07, 2015 at 14:57 PM EDT
